Primary pulmonary lymphoepithelioma-like carcinoma

Fan, Ying; Li, Chenghui; Qin, Jing; Lu, Hongyang

doi:10.1007/s12032-020-1344-3

Cited by 14 publications

(15 citation statements)

References 54 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Our patients had a median age of 55.6 years (range 53-58) and were predominantly female. The patients were all nonsmokers, which is quite a distinctive demographic characteristic of PPLELC, as it generally affects younger Asian nonsmoking females ( 18 ). The features of PPLELC that distinguish it from other subtypes of NSCLC indicate that PPLELC is a unique subtype of lung cancer.…”

Section: Discussionmentioning

confidence: 99%

“…The features of PPLELC that distinguish it from other subtypes of NSCLC indicate that PPLELC is a unique subtype of lung cancer. In addition, epidemiological differences in PPLELC exist across different regions worldwide ( 18 , 19 ). As reported by other studies ( 13 , 20 , 21 ), PPLELC in our study mainly originated in the right lower lobe and rarely in the right upper lobe, with a median diameter of 5.1 cm.…”

Section: Discussionmentioning

confidence: 99%

“…All of the patients had EBER positivity, and two showed evidence of EBV infection; although it is widely believed that a connection exists between EBV infection and the development of PPLELC ( 3 ), conflicting findings have been reported in Western populations ( 22 ). In vitro studies of nasopharyngeal carcinoma have shown that EBV has the ability to upregulate PD-L1 expression through IFN-γ and latent membrane protein 1 ( 18 ). The results of our study revealed a median PD-L1 TPS of 40%, and 60% of the patients had low PD-L1 expression, which is similar to the findings reported in the study by Zhanhong Xie et al.…”

Section: Discussionmentioning

confidence: 99%

See 2 more Smart Citations

Immune Checkpoint Blockade Therapy May Be a Feasible Option for Primary Pulmonary Lymphoepithelioma-like Carcinoma

Wu¹,

Xian²,

Wang³

et al. 2021

Front. Oncol.

View full text Add to dashboard Cite

Primary pulmonary lymphoepithelioma-like carcinoma (PPLELC) is a rare subtype of non-small cell lung cancer (NSCLC) for which there is currently no recognized treatment. Recently, favorable immune checkpoint blockade responses have been observed in PPLELC. This study aimed to review the effects of this regimen in patients with advanced PPLELC. PPLELC patients treated with immune checkpoint inhibitors at West China Hospital between January 2008 and December 2019 were retrospectively identified. Demographic parameters and antitumor treatment details were retrieved and reviewed. Among 128 patients diagnosed with PPLELC, 5 who received immune checkpoint inhibitors at advanced stages were included in the analysis. All of these patients were female nonsmokers with a median age of 55.6 (range 53-58) years at diagnosis. Their median PD-L1 expression was 40% (range, 30-80%). Although the patients underwent surgeries, chemotherapy and radiotherapy, all the treatments failed. Immune checkpoint inhibitors were administered palliatively, and three patients responded favorably, with the best overall response being partial remission (PR). Thus, immune checkpoint inhibitors may be a promising treatment for advanced PPLELC, and large clinical trials are warranted to obtain more evidence regarding this regimen.

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Discussionmentioning

confidence: 99%

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Immune Checkpoint Blockade Therapy May Be a Feasible Option for Primary Pulmonary Lymphoepithelioma-like Carcinoma

Wu¹,

Xian²,

Wang³

et al. 2021

Front. Oncol.

View full text Add to dashboard Cite

show abstract

“…5 Due to its low incidence and the lack of information regarding the molecular mechanism of its tumorigenesis, treatment strategies for pLELC have not been fully defined, although surgery, chemotherapy, and radiation are often used. 6 With the rise of immunotherapies, monoclonal antibodies against programmed cell death ligand 1 (PD-L1) have attracted researchers' attention in pLELC treatment. A potential benefit has been reported in some pLELC cases.…”

Section: Introductionmentioning

confidence: 99%

Molecular characteristics of primary pulmonary lymphoepithelioma-like carcinoma based on integrated genomic analyses

Chen

Dai

Zhou

et al. 2021

Sig Transduct Target Ther

View full text Add to dashboard Cite

Primary pulmonary lymphoepithelioma-like carcinoma (pLELC) is a rare non-small cell lung cancer (NSCLC) subtype. Clinical features have been described in our previous report, but molecular characteristics remain unclear. Herein, pLELC genomic features were explored. Among 41,574 lung cancers, 128 pLELCs and 162 non-pLELC NSCLCs were enrolled. Programmed cell death ligand 1 (PD-L1) and protein 53 (p53) expression was detected in 47 surgically resected pLELC samples by immunohistochemical assays. Multiomics genomic analyses, including whole-genome sequencing (WGS), RNA whole-transcriptome sequencing (RNA-seq), and Epstein-Barr virus (EBV) integration analyses, were performed on eight frozen pLELC tissues and compared with 50 lung adenocarcinomas (LUADs) and 50 lung squamous cell carcinomas (LUSCs) from The Cancer Genome Atlas (TCGA) and another 26 EBV-positive nasopharynx cancers (EBV+-NPCs). Progression-free survival (PFS) and overall survival (OS) of pLELC patients were better than those of non-pLELC patients. High PD-L1 or p53 expression was associated with extended disease-free survival (DFS). pLELC had 14 frequently mutated genes (FMGs). Somatically mutated genes and enrichment of genetic lesions were found, which differed from observations in LUAD, LUSC, and EBV+-nasopharyngeal carcinoma (NPC). Three tumor-associated genes, zinc finger and BTB domain-containing 16 (ZBTB16), peroxisome proliferator activated receptor gamma (PPARG), and transforming growth factor beta receptor 2 (TGFBR2), were downregulated with copy number variation (CNV) loss. EBV was prone to integrating into intergenic and intronic regions with two upregulated miR-BamH1-A rightward transcripts (BARTs), BART5-3P and BART20-3P. Our findings reveal that pLELC has a distinct genomic signature. Three tumor-associated genes with CNV loss and two miR-BARTs might be involved in pLELC tumorigenesis.

show abstract

“…All of the patients had EBER positivity, and two showed evidence of EBV infection; although it is widely believed that a connection exists between EBV infection and the development of PPLELC (3), conflicting findings have been reported in Western populations (22). In vitro studies of nasopharyngeal carcinoma have shown that EBV has the ability to upregulate PD-L1 expression through IFN-g and latent membrane protein 1 (18). The results of our study revealed a median PD-L1 TPS of 40%, and 60% of the patients had low PD-L1 expression, which is similar to the findings reported in the study by Zhanhong Xie et al (23).…”

Section: Discussionmentioning

confidence: 99%

DataSheet_1.docx

View full text Add to dashboard Cite

Primary pulmonary lymphoepithelioma-like carcinoma

Cited by 14 publications

References 54 publications

Immune Checkpoint Blockade Therapy May Be a Feasible Option for Primary Pulmonary Lymphoepithelioma-like Carcinoma

Immune Checkpoint Blockade Therapy May Be a Feasible Option for Primary Pulmonary Lymphoepithelioma-like Carcinoma

Molecular characteristics of primary pulmonary lymphoepithelioma-like carcinoma based on integrated genomic analyses

DataSheet_1.docx

Contact Info

Product

Resources

About